Adrenomedullin is a therapeutic target in colorectal cancer

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2041-2050

  Wang, Liangjing ^a,b   Gala, Manish ^a   Yamamoto, Masayoshi ^a   Pino, Maria S ^a,c   Kikuchi, Hirotoshi ^a   Shue, Daniel S ^a   Shirasawa, Senji ^d   Austin, Thomas R ^a   Lynch, Maureen P ^a   Rueda, Bo R ^a   Zukerberg, Lawrence R ^a   Chung, Daniel C ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c Medical Oncology Unit   (Italy)

^d FUKUOKA UNIVERSITY   (Japan)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

adrenomedullin; colorectal cancers; hypoxia; K ras

Indexed keywords

ADRENOMEDULLIN; COMPLEMENTARY DNA;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL INVASION; CELL STRAIN CACO 2; CELL STRAIN HCT116; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING;

ADRENOMEDULLIN; COLORECTAL CANCERS; HYPOXIA; K-RAS;

ADRENOMEDULLIN; ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896725549     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28542     Document Type: Article

References (38)

1. Wilson WR, Hay MP,. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410.
2. Bertout JA, Patel SA, Simon MC,. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-75.
3. Rankin EB, Giaccia AJ,. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-85.
4. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005; 11: 992-7.
5. Kikuchi H, Pino MS, Zeng M, et al. Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. Cancer Res 2009; 69: 8499-506.
6. Zeng M, Kikuchi H, Pino MS, et al. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One 2010; 5: e10966.
7. Mizukami Y, Fujiki K, Duerr EM, et al. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006; 281: 13957-63.
8. Zhang X, Gaspard JP, Chung DC,. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001; 61: 6050-4.
9. Bos JL,. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
10. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
11. Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 2005; 5: 1283-6.
12. Hoogwater FJ, Nijkamp MW, Smakman N, et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010; 138: 2357-67.
13. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 2009; 325: 1555-9.
14. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-60.
15. Nikitenko LL, Fox SB, Kehoe S, et al. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006; 94: 1-7.
16. Ribatti D, Nico B, Spinazzi R, et al. The role of adrenomedullin in angiogenesis. Peptides 2005; 26: 1670-5.
17. Ishikawa T, Chen J, Wang J, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003; 22: 1238-42.
18. Martínez A, Vos M, Guédez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002; 94: 1226-37.
19. Iimuro S, Shindo T, Moriyama N, et al. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004; 95: 415-23.
20. Oehler MK, Norbury C, Hague S, et al. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 2001; 20: 2937-45.
21. Shirasawa S, Furuse M, Yokoyama N, et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993; 260: 85-8.
22. Pino MS, Kikuchi H, Zeng M, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability. Gastroenterology 2010; 138: 1406-17.
23. Oehler MK, Fischer DC, Orlowska-Volk M, et al. Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer. Br J Cancer 2003; 89: 1927-33.
24. Telang S, Yalcin A, Clem AL, et al. Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 2006; 25: 7225-34.
25. Benita Y, Kikuchi H, Smith AD, et al. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009; 37: 4587-602.
26. Schödel J, Oikonomopoulos S, Ragoussis J, et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 2011; 117: e207-e217.
27. Grimmer C, Balbus N, Lang U, et al. Regulation of type II collagen synthesis during osteoarthritis by prolyl-4-hydroxylases: possible influence of low oxygen levels. Am J Pathol 2006; 169: 491-502.
28. Washimine H, Asada Y, Kitamura K, et al. Immunohistochemical identification of adrenomedullin in human, rat, and porcine tissue. Histochem Cell Biol 1995; 103: 251-4.
29. Hata K, Takebayashi Y, Akiba S, et al. Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 2000; 6: 867-72.
30. Okuyama H, Endo H, Akashika T, et al. Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res 2010; 70: 10213-23.
31. Garayoa M, Martínez A, Lee S, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000; 14: 848-62.
32. Nikitenko LL, Smith DM, Bicknell R, et al. Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J 2003; 17: 1499-501.
33. Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007; 121: 21-32.
34. Chun SY, Johnson C, Washburn JG, et al. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Mol Cancer 2010; 9: 293.
35. Ramachandran V, Arumugam T, Hwang RF, et al. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res 2007; 67: 2666-75.
36. Kaafarani I, Fernandez-Sauze S, Berenguer C, et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J 2009; 23: 3424-35.
37. Winder T, Lenz HJ,. Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. Gastroenterology 2010; 138: 2163-76.
38. Oladipupo S, Hu S, Kovalski J, et al. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc Natl Acad Sci USA 2011; 108: 13264-9.